Drug or treatment

Upadacitinib clinical trials

• 25Clinical trials
• 37Countries

Newest trials

All recruiting trials (25)

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Upadacitinib for Severe Alopecia Areata in Children

  This study tests whether upadacitinib can safely help children with severe alopecia areata grow back hair, compared with placebo.

  Recruiting at 14 sites Phase 3 AbbVie · Los Angeles, California and 13 other locations · NCT07772492

• Upadacitinib for Eosinophilic Esophagitis in adults not responding to standard therapy

  This study tests whether upadacitinib, taken with topical corticosteroids, can reduce disease activity in adults with eosinophilic esophagitis who still have symptoms.

  Recruiting Phase 2 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07588568

• Upadacitinib versus infliximab for second-line treatment of acute severe ulcerative colitis

  This trial will see if upadacitinib or infliximab works better to induce remission in adults with acute severe ulcerative colitis who need second-line therapy.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07550673

• Upadacitinib versus corticosteroids for first-line treatment of acute severe ulcerative colitis

  This test will see if upadacitinib works as well as corticosteroids to induce remission in adults with acute severe ulcerative colitis.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07546097

• TNFi plus low-dose upadacitinib versus TNFi dose intensification for Crohn's disease with suboptimal response

  This trial tests whether adding low-dose upadacitinib to a standard TNF blocker helps adults with moderate-to-severe Crohn's disease who haven't responded well to standard-dose infliximab or adalimumab, compared with increasing the TNFi dose.

  Recruiting Phase 4 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07510191

• Upadacitinib for adults with erosive mucosal lichen planus or lichen planopilaris

  This trial tests whether upadacitinib can help adults with erosive mucosal lichen planus or lPP by comparing it to placebo.

  Recruiting at 4 sites Phase 2 Centre Hospitalier Universitaire de Nice · Nice, Alpes Maritimes and 4 other locations · NCT07492251

• Upadacitinib with or without vedolizumab for induction in moderate-to-severe ulcerative colitis

  This study tests whether adding vedolizumab to upadacitinib helps adults with moderate-to-severe ulcerative colitis achieve better short-term (8-week) control than upadacitinib alone.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Foshan, Guangdong and 5 other locations · NCT07442045

• Upadacitinib plus steroids vs steroids alone for acute severe ulcerative colitis

  This will test whether adding upadacitinib (Rinvoq) to corticosteroids helps adults with acute severe ulcerative colitis, whether treated as inpatients or outpatients, recover faster than steroids alone.

  Recruiting Phase 4 University of Michigan · Ann Arbor, Michigan · NCT07258771

• Comparing five advanced treatments for axial spondyloarthritis and psoriatic arthritis

  This project will see how well bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor work for adults with axSpA or PsA who have just started one of these medicines, using medical records and patient surveys.

  Recruiting Adelphi Real World · Bath, Somerset · NCT07166315

• Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease

  This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.

  Recruiting at 25 sites AbbVie · Castellana Grotte, Bari and 24 other locations · NCT07073079

• Evaluating Upadacitinib for treating relapsing polychondritis

  This study is testing if a new medication called Upadacitinib can help adults with relapsing polychondritis feel better compared to standard treatments like steroids and immunosuppressants.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06873100

• Evaluating Upadacitinib for Ulcerative Colitis in Chinese Adults

  This study is testing how well upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis.

  Recruiting at 3 sites AbbVie · Guangzhou, Guangdong and 2 other locations · NCT06838845

• Evaluating Upadacitinib for Inflammatory Bowel Disease

  This study is testing how well the oral medication Upadacitinib works for people in China with Inflammatory Bowel Disease who haven't responded to other treatments.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT06780683

• Comparing the effectiveness of Upadacitinib and TNF inhibitors for rheumatoid arthritis in Germany

  This study is testing whether Upadacitinib works better than traditional TNF inhibitors for adults with moderate to severe rheumatoid arthritis in Germany.

  Recruiting at 74 sites AbbVie · Freiburg im Breisgau, Baden-Wurttemberg and 74 other locations · NCT06712628

• Upadacitinib for eyelid dermatitis in adults

  This study tests whether upadacitinib can help adults with eyelid dermatitis that hasn’t improved after standard creams.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT06684522

• Assessing Upadacitinib Treatment in Adults with Inflammatory Bowel Disease in Belgium

  This study is testing how well the medication upadacitinib works and how safe it is for adults with moderate to severe ulcerative colitis and Crohn's disease in Belgium over three years.

  Recruiting at 11 sites AbbVie · Bonheiden, Antwerpen and 10 other locations · NCT06581042

• Comparing dual-target therapy with intensified Ustekinumab for Crohn's disease

  This study is testing if a new combination treatment of Ustekinumab and Upadacitinib can help people with Crohn's disease feel better compared to a higher dose of Ustekinumab alone.

  Recruiting Phase 4 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06520397

• Using Upadacitinib to Improve Vitiligo Treatment

  This study is testing if adding a medication called upadacitinib after a skin treatment can help adults with vitiligo see better results.

  Recruiting Jilin University · Changchun, Jilin · NCT06454461

• Evaluating Upadacitinib for Psoriatic Arthritis and Spondyloarthritis

  This study is testing if Upadacitinib can help people with active Psoriatic Arthritis and Spondyloarthritis feel better compared to a placebo.

  Recruiting at 5 sites Phase 4 Care Arthritis LTD. · Cleveland, Ohio and 4 other locations · NCT06454188

• Combining vedolizumab and upadacitinib for treating Crohn's Disease

  This study is testing if combining two medications, vedolizumab and upadacitinib, can help adults with moderate to severe Crohn's Disease feel better compared to using vedolizumab alone.

  Recruiting at 8 sites Phase 3 Takeda · La Jolla, California and 137 other locations · NCT06227910

• Combining Vedolizumab and Upadacitinib for Ulcerative Colitis Treatment

  This study is testing if combining two medications, Vedolizumab and Upadacitinib, can help people with moderate to severe ulcerative colitis feel better faster and stay well longer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06095596

• Assessing the effectiveness of upadacitinib for treating Crohn's disease in Japan

  This study is testing if upadacitinib can help teenagers and adults in Japan with moderate to severe Crohn's disease feel better and stay safe while using the medication.

  Recruiting at 104 sites AbbVie · Anjo-shi, Aichi-ken and 103 other locations · NCT06023030

• Upadacitinib tablets for severe alopecia areata in adolescents and adults

  This trial will try upadacitinib tablets to see if they are safe and help regrow hair in adolescents and adults with severe alopecia areata.

  Recruiting at 46 sites Phase 3 AbbVie · Birmingham, Alabama and 271 other locations · NCT06012240

• Evaluating Upadacitinib and Tocilizumab for Treating Systemic Juvenile Idiopathic Arthritis in Children

  This study is testing whether a new drug called upadacitinib is safe and effective for children and teens with systemic juvenile idiopathic arthritis compared to an existing treatment called tocilizumab.

  Recruiting at 40 sites Phase 3 AbbVie · Phoenix, Arizona and 44 other locations · NCT05609630

Quick answers

How many clinical trials of Upadacitinib are recruiting right now?

25, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 37 countries. The most sites are in China (12 trials), United States (9 trials), United Kingdom (4 trials), Italy (4 trials), Japan (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 4: 6, Phase 3: 4, Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →